Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 8/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 8/20 | 0.53 |
| ▸ | RELA | Q04206 | 8/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25195063 | 0.91 | NFKB1 (0.56) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL25190622 | 0.90 | NFKB1 (0.55) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL25279027 | 0.90 | NFKB1 (0.55) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL25200388 | 0.89 | NFKB1 (0.62) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL25214837 | 0.86 | NFKB1 (0.51) | NFKB1NFKB2RELASLC5A1SLC5A2 | |
| SCHEMBL25191756 | 0.85 | NFKB1 (0.58) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL16150089 | 0.80 | SLC5A1 (0.72) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL16150086 | 0.80 | SLC5A1 (0.72) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL25188670 | 0.78 | NFKB1 (0.61) | NFKB1NFKB2RELAABCG2SLC5A1 | |
| SCHEMBL25283130 | 0.78 | NFKB1 (0.69) | NFKB1NFKB2RELAABCG2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | NFKB1 1669/4885NFKB2 1728/4885RELA 1254/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | NFKB1 2437/4885NFKB2 2273/4885RELA 1879/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | NFKB1 2437/4885NFKB2 2273/4885RELA 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.